October 27, 2021
Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications
4th Annual TPD Summit
Other
Read More
October 27, 2021
Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers
4th Annual TPD Summit
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
October 26, 2021
TPD Workshop: De-risking Clinical Development of a Novel Protein Degrader
4th Annual TPD Summit
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
September 21, 2021
Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease
European Protein Degradation Congress
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
September 15, 2021
Inventing New Medicines with Targeted Protein Degradation
Undruggable Leaders Forum
Read More
July 12, 2021
Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL
13th Annual T-Cell Lymphoma Forum
Other
Read More
June 20, 2021
KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models
16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
Other
Read More
May 26, 2021
Drugging Tissue-Restricted E3 Ligases
Ligase Targeting Drug Development Summit
Read More
May 10, 2021
IRAK4 Degradation Abrogates Cytokine Release and Improves Disease Endpoints in Murine Models of IL-33/36- as well as Th17-driven Inflammation
American Association of Immunologists’ Virtual IMMUNOLOGY2021™ Annual Meeting
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More
May 3, 2021
Multiple Mediators of Inflammation Correlate with IRAK4 Expression in the Skin of Hidradenitis Suppurativa Patients and are Blocked by the IRAK4 Degrader KT-474 in TLR-activated Monocytes
Society for Investigative Dermatology (SID) 2021 Annual Meeting
Hidradenitis Suppurativa (HS)
Atopic Dermatitis (AD)
Read More